MA-ULTIVUE
9.3.2022 11:02:08 CET | Business Wire | Press release
Ultivue, Inc., an industry leader in multiplexing tools and novel image analysis solutions for tissue biomarker studies, and Aignostics GmbH, a global leader in Artificial Intelligence (AI) powered precision diagnostics focused on pathology to assist with research, clinical trials and CDx development, announced a partnership to collaborate on the co-development of AI-powered spatial multiplexed immunophenotype solutions for translational research groups and Biopharma.
The companies have already been working together since early 2021 to adapt Aignostics’ client platform to support visualization and analysis for some of Ultivue’s products and services, as well as provisioning of results and corresponding reports. The resulting co-developed platform will now be made available to joint clients. Additionally, proof of concept work conducted on the Ultivue 12-plex Immunophenotyping biomarker panel in over 1,000 clinical NSCLC cases has demonstrated encouraging results for the capacity of AI-based analysis of multiplexed images for more consistent and reproducible readouts at scale. These results will be published later this year and respective AI models made available via the platform.
The companies are now expanding their relationship under a co-marketing agreement to offer the multiplex immunofluorescence (mIF) platform to their respective biotech and pharma clients, initially for research use, with a GCP-compliant version to follow later this year. Moreover, Ultivue and Aignostics will offer AI-powered image analysis services within the platform via Aignostics “Explainable AI” approach for the consistent and precise analysis of mIF cohorts at scale, for both translational research and clinical trial research services in Ultivue’s CLIA accredited clinical research laboratory. “We are excited to extend our workflow offering to include mIF AI for highly automated image analysis by partnering with Aignostics,” says Florian Leiss, VP Digital Health at Ultivue. “Improved viewing capabilities enable us to interactively explore the interplay of mIF-labeled cell populations in the histological context of same-slide H&E.”
“We believe that development of Ultivue’s assays with our AI-powered image analysis will create insights from data at scale that are unprecedented in spatial biology today. We are excited to start offering this approach to our clients for translational science and clinical trials,” said Viktor Matyas, CEO of Aignostics.
Besides offering research and development services to its clients, Ultivue and Aignostics will also develop products for standardized analysis of certain Ultivue products, paving the way for more widespread use of these technologies in both clinical trials and clinical routine.
About Ultivue
Ultivue provides researchers and scientists in translational medicine with multiplex biomarker assays for tissue phenotyping and digital pathology. Its proprietary InSituPlex® technology enables advanced exploration and interrogation of tissue samples for precision medicine research. These highly customizable solutions coupled with our scientific consultative approach strengthen and accelerate biomarker discovery and drug development programs. Learn more at Ultivue.com.
About Aignostics
Aignostics, a Berlin based company with offices in the US, is a digital pathology company dedicated to novel precision diagnostics through the use of a proprietary “Explainable AI” platform in pre-clinical and translational research and clinical trials. The use of such technology is expected to be crucial to implementation of AI-powered algorithms in routine diagnostics in order to verify (explain) the model’s decision outputs. Additionally, through its close alignment to Charité and TU Berlin amongst other collaborators, only Aignostics offers the combination of data access, sample testing and pathology expertise to develop digital pathology algorithms spanning multi-modal biomarker assay detection systems such as H&E, IHC and mIF, amongst others.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220309005149/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Agendia to Showcase New Research on AI-Driven Digital Pathology at ESMO 20266.10.2026 14:00:00 CEST | Press release
Podium presentation by Co-Founder and Chief Research Officer Laura van ’t Veer introduces an AI-driven approach to MammaPrintTwo additional poster presentations from the FLEX Study Agendia, Inc., a leader in precision oncology for breast cancer, announced today that it will present new research during a podium presentation on the development of an artificial intelligence (AI)-driven digital pathology approach for MammaPrintⓇ at the European Society for Medical Oncology (ESMO) Congress 2026, which takes place October 23 to 27, 2026, in Madrid. The company will also present two additional posters at ESMO. AI-driven digital pathology approaches are rapidly developing to expand access to genomic testing globally. Agendia’s first presentation, submitted as a late-breaking abstract, focuses on the development and validation of an AI-driven MammaPrint approach based on the analysis of routine whole slide images of breast cancer tissue. The following are details of the late-breaking abstract t
ExaGrid Named Finalist for the MSP Channel Insights Awards 20266.10.2026 14:00:00 CEST | Press release
ExaGrid Nominated in 7 Categories for Industry Awards ExaGrid, the world’s largest independent backup storage vendor providing Tiered Backup Storage for the fastest backups and restores, largest scale-out system with deduplication, and the most comprehensive security and AI-Powered Retention Time-Lock for Ransomware Recovery, today announced that it has been nominated in seven categories for the annual MSP Channel Insights Awards. The MSP Channel Insights Awards celebrate innovation, expertise and success across the IT channel—recognizing the Managed Service Providers (MSPs), vendors, distributors, resellers and technology leaders driving customer outcomes and business growth. Voting to determine the winner in each category is underway now and closes on October 30, 2026. Winners of the MSP Channel Insights Awards will be announced on November 26, 2026, at an awards ceremony in London. The award categories that ExaGrid has been nominated for include: Vendor of the Year Vendor Channel Pr
IFF Identifies the Life-Stage Insights Shaping Dairy’s Future6.10.2026 13:00:00 CEST | Press release
IFF (NYSE: IFF)—a global leader in flavors, fragrances and health and biosciences, published its latest resource, Dear Dairy: The Life Stages Guide. This strategic guide reveals how manufacturers can unlock new opportunities by aligning dairy innovation with consumers' evolving needs throughout life. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261005026164/en/ “Dairy is one of the few categories that evolves alongside consumers throughout their lives,” said Rogerio de Almeida Prado, vice president of Global Dairy & BBC (Bakery, Bars and Confectionery) for IFF Taste. “Over time, expectations change. What builds trust in childhood may need to support identity, convenience or vitality later in life. The next wave of dairy innovation will be defined not by a single trend, ingredient or claim, but by an understanding of what consumers need at different times of their lives — and why.” Drawing on insights from Panoptic™, IFF's
Invivoscribe® Advances Molecular Clonality Testing Portfolio with Comprehensive LymphoTrack® Flex Suite6.10.2026 12:15:00 CEST | Press release
New ultra-high sensitivity tests enable objective, automation-ready, high-throughput clonality and MRD workflow. Invivoscribe, a global leader in precision diagnostics and measurable residual disease (MRD) testing, today announced the launch of the complete LymphoTrack Flex suite, an integrated next-generation sequencing (NGS) solution to identify and track immunoglobulin and T-cell receptor gene rearrangements. As NGS-based immune receptor MRD analysis moves from academic laboratories into routine use in oncology research centers, the demand for standardized, high-throughput workflows is accelerating. Laboratories are seeking both greater efficiency and ultra-high sensitivity. This requires increasing DNA inputs while ensuring higher testing throughput and analytical performance. Translational programs need testing that is both reproducible and scalable across sites. LymphoTrack Flex meets these demands, bringing seven molecular targets (IGHV leader, IGH FR1, IGH FR2, IGH FR3, IGK, TR
Degreed Agents Enable Every Leader to Upskill Their Organization with Ease6.10.2026 12:00:00 CEST | Press release
Degreed was born with the mission to help everyone get credit for all of their learning and skills. Today, the company announces the latest phase of that journey with the release of Degreed agents, a connected system of AI agents that lets leaders and L&D teams automate personalized learning and skill building. Leaders set the direction, agents do the work, and together they form the foundation of a hybrid operating system for their workforce. Businesses today run workforce transformations as a relay. The CEO sets a mandate to get everyone AI-fluent. A talent leader then defines the end state while managers try to spot gaps on their own teams. L&D pulls reports by hand and builds what they can. Each handoff adds a delay. Now, agents can orchestrate all of that in real time. Degreed agents notice details that matter, like a promotion, a skill gap, or an engagement dip, and act on them without requiring a manager to notice, an admin to flag it, or L&D to build it. At launch, agents build
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom